SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-22-028242
Filing Date
2022-11-03
Accepted
2022-11-03 16:40:33
Documents
85
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q akba-20220930.htm   iXBRL 10-Q 2256646
2 EX-10.2 exhibit102-formofformofame.htm EX-10.2 7570
3 EX-31.1 exhibit311-q32022.htm EX-31.1 11368
4 EX-31.2 exhibit312-q32022.htm EX-31.2 11408
5 EX-32.1 exhibit321-q32022.htm EX-32.1 9285
  Complete submission text file 0001628280-22-028242.txt   9461157

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akba-20220930.xsd EX-101.SCH 85029
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT akba-20220930_cal.xml EX-101.CAL 97611
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akba-20220930_def.xml EX-101.DEF 363441
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akba-20220930_lab.xml EX-101.LAB 776520
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akba-20220930_pre.xml EX-101.PRE 539930
79 EXTRACTED XBRL INSTANCE DOCUMENT akba-20220930_htm.xml XML 1403223
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36352 | Film No.: 221358676
SIC: 2834 Pharmaceutical Preparations